{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:22:17Z","timestamp":1769862137151,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007533","name":"Kobayashi Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP-19K09198"],"award-info":[{"award-number":["JP-19K09198"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP-23K08133"],"award-info":[{"award-number":["JP-23K08133"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP-23K19513"],"award-info":[{"award-number":["JP-23K19513"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Grant of the Princess Takamatsu Cancer Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1245\/s10434-024-16065-3","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T22:02:09Z","timestamp":1724450529000},"page":"8627-8637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Association of Transferrin Receptor with Prognosis and Biologic Role in Intrahepatic Cholangiocarcinoma"],"prefix":"10.1245","volume":"31","author":[{"given":"Katsuya","family":"Toshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0382-2520","authenticated-orcid":false,"given":"Shinji","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Iseda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Bekki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Yoshiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Toshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoharu","family":"Yoshizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"16065_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","volume":"79","author":"European Association for the Study of the Liver","year":"2023","unstructured":"European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;79:181\u2013208.","journal-title":"J Hepatol."},{"key":"16065_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"16065_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428\u201344.","journal-title":"Lancet."},{"key":"16065_CR4","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","volume":"29","author":"MC de Jong","year":"2011","unstructured":"de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140\u20135.","journal-title":"J Clin Oncol."},{"key":"16065_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh DY, Lee KH, Lee DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022;7:522\u201332.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"16065_CR6","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell."},{"key":"16065_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22:381\u201396.","journal-title":"Nat Rev Cancer."},{"key":"16065_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/cas.15981","volume":"115","author":"K Toshida","year":"2024","unstructured":"Toshida K, Itoh S, Iseda N, et al. Impact of TP53-induced glycolysis and apoptosis regulator on malignant activity and resistance to ferroptosis in intrahepatic cholangiocarcinoma. Cancer Sci. 2024;115:170\u201383.","journal-title":"Cancer Sci."},{"key":"16065_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.molcel.2015.06.011","volume":"59","author":"M Gao","year":"2015","unstructured":"Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell. 2015;59:298\u2013308.","journal-title":"Mol Cell."},{"key":"16065_CR10","doi-asserted-by":"publisher","first-page":"8675","DOI":"10.1245\/s10434-023-14053-7","volume":"30","author":"M Hiromatsu","year":"2023","unstructured":"Hiromatsu M, Toshida K, Itoh S, et al. Transferrin receptor is associated with sensitivity to ferroptosis inducers in hepatocellular carcinoma. Ann Surg Oncol. 2023;30:8675\u201389.","journal-title":"Ann Surg Oncol."},{"key":"16065_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00595-011-0108-2","volume":"42","author":"S Itoh","year":"2012","unstructured":"Itoh S, Shirabe K, Taketomi A, et al. Zero mortality in more than 300 hepatic resections: validity of preoperative volumetric analysis. Surg Today. 2012;42:435\u201340.","journal-title":"Surg Today."},{"key":"16065_CR12","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1007\/s00268-020-05682-0","volume":"44","author":"K Toshida","year":"2020","unstructured":"Toshida K, Minagawa R, Kayashima H, et al. The effect of prone positioning as postoperative physiotherapy to prevent atelectasis after hepatectomy. World J Surg. 2020;44:3893\u2013900.","journal-title":"World J Surg."},{"key":"16065_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/jhbp.154","volume":"22","author":"S Aishima","year":"2015","unstructured":"Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci. 2015;22:94\u2013100.","journal-title":"J Hepatobiliary Pancreat Sci."},{"key":"16065_CR14","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/hep.31206","volume":"72","author":"S Itoh","year":"2020","unstructured":"Itoh S, Yoshizumi T, Yugawa K, et al. Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation. Hepatology. 2020;72:1987\u201399.","journal-title":"Hepatology."},{"key":"16065_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/his.13847","volume":"75","author":"M Adachi","year":"2019","unstructured":"Adachi M, Kai K, Yamaji K, et al. Transferrin receptor 1 overexpression is associated with tumour de-differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma. Histopathology. 2019;75:63\u201373.","journal-title":"Histopathology."},{"key":"16065_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/cas.15644","volume":"114","author":"K Toshida","year":"2023","unstructured":"Toshida K, Itoh S, Harada N, et al. Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma. Cancer Sci. 2023;114:937\u201347.","journal-title":"Cancer Sci."},{"key":"16065_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3164\/jcbn.10-24","volume":"47","author":"S Itoh","year":"2010","unstructured":"Itoh S, Taketomi A, Harimoto N, et al. Antineoplastic effects of gamma linolenic acid on hepatocellular carcinoma cell lines. J Clin Biochem Nutr. 2010;47:81\u201390.","journal-title":"J Clin Biochem Nutr."},{"issue":"2509\u201318","key":"16065_CR18","first-page":"18.e1","volume":"138","author":"W Lin","year":"2010","unstructured":"Lin W, Tsai WL, Shao RX, et al. Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology. 2010;138(2509\u201318):18.e1.","journal-title":"Gastroenterology."},{"key":"16065_CR19","doi-asserted-by":"publisher","first-page":"154259","DOI":"10.1016\/j.phymed.2022.154259","volume":"104","author":"J Zhang","year":"2022","unstructured":"Zhang J, Li Y, Wan J, Zhang M, Li C, Lin J. Artesunate: a review of its therapeutic insights in respiratory diseases. Phytomedicine. 2022;104:154259.","journal-title":"Phytomedicine."},{"key":"16065_CR20","doi-asserted-by":"publisher","first-page":"97920","DOI":"10.18632\/oncotarget.18542","volume":"8","author":"CY Ock","year":"2017","unstructured":"Ock CY, Kim S, Keam B, et al. Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. Oncotarget. 2017;8:97920\u20137.","journal-title":"Oncotarget."},{"key":"16065_CR21","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365.","journal-title":"Lancet."},{"key":"16065_CR22","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015.","journal-title":"NEJM Evid."},{"key":"16065_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0092-8674(04)00343-5","volume":"117","author":"MW Hentze","year":"2004","unstructured":"Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004;117:285\u201397.","journal-title":"Cell."},{"key":"16065_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.bbagen.2011.07.016","volume":"1820","author":"TR Daniels","year":"2012","unstructured":"Daniels TR, Bernabeu E, Rodr\u00edguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820:291\u2013317.","journal-title":"Biochim Biophys Acta."},{"key":"16065_CR25","doi-asserted-by":"publisher","first-page":"101042831771765","DOI":"10.1177\/1010428317717655","volume":"39","author":"W Jamnongkan","year":"2017","unstructured":"Jamnongkan W, Thanan R, Techasen A, et al. Upregulation of transferrin receptor-1 induces cholangiocarcinoma progression via induction of labile iron pool. Tumour Biol. 2017;39:1010428317717655.","journal-title":"Tumour Biol."},{"key":"16065_CR26","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","volume":"357","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695\u2013704.","journal-title":"N Engl J Med."},{"key":"16065_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00280-017-3358-x","volume":"80","author":"JCF Quintanilha","year":"2017","unstructured":"Quintanilha JCF, de Sousa VM, Visacri MB, et al. Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity. Cancer Chemother Pharmacol. 2017;80:223\u201333.","journal-title":"Cancer Chemother Pharmacol."},{"key":"16065_CR28","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.3390\/ijms20143384","volume":"20","author":"V Cocetta","year":"2019","unstructured":"Cocetta V, Ragazzi E, Montopoli M. Mitochondrial involvement in cisplatin resistance. Int J Mol Sci. 2019;20:3384.","journal-title":"Int J Mol Sci."},{"key":"16065_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12935-021-02081-w","volume":"21","author":"M Deng","year":"2021","unstructured":"Deng M, Li SH, Fu X, et al. Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients. Cancer Cell Int. 2021;21:371.","journal-title":"Cancer Cell Int."},{"key":"16065_CR30","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/hep4.1715","volume":"5","author":"S Itoh","year":"2021","unstructured":"Itoh S, Yoshizumi T, Kitamura Y, et al. Impact of metabolic activity in hepatocellular carcinoma: association with immune status and vascular formation. Hepatol Commun. 2021;5:1278\u201389.","journal-title":"Hepatol Commun."},{"key":"16065_CR31","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28:1599\u2013611.","journal-title":"Nat Med."},{"key":"16065_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.canlet.2019.08.005","volume":"464","author":"L Fournel","year":"2019","unstructured":"Fournel L, Wu Z, Stadler N, et al. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Lett. 2019;464:5\u201314.","journal-title":"Cancer Lett."},{"key":"16065_CR33","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1002\/cbin.11697","volume":"45","author":"ZS Zhang","year":"2021","unstructured":"Zhang ZS, Yang RH, Yao X, et al. HGF\/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma. Cell Biol Int. 2021;45:2521\u201333.","journal-title":"Cell Biol Int."},{"key":"16065_CR34","doi-asserted-by":"publisher","first-page":"eabq4722","DOI":"10.1126\/sciadv.abq4722","volume":"8","author":"Q Wang","year":"2022","unstructured":"Wang Q, Cao Y, Shen L, et al. Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs. Sci Adv. 2022;8:eabq4722.","journal-title":"Sci Adv."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16065-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16065-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16065-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:04:26Z","timestamp":1731071066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16065-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":34,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["16065"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16065-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.T., S.I. and other co-authors declare that we have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"Approval of research protocol by an Institutional Reviewer Board: This study was approved by the Clinical Research Ethics Committee of Kyushu University (approval code: 2021-467).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"All the participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}